ReviewFuture microbiology2018
Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside.
Review in Future microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolutionary trends in antifungal resistance: a meta-analysis.Microbiology spectrum · 2024Pooled it
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- Managing Breakthrough Fungal Infections in Hematologic Patients: Determinants and Practical Management from a Latin American Perspective on Behalf of INFOCUS LATAM-ISHAM Working Group.Microorganisms · 2026Review
- α-1,3-Glucan-Driven Remodeling of the Conidial Cell Wall in anJournal of the American Chemical Society · 2026Article
- Identification ofMicrobiology spectrum · 2026Article
- Endophytic nanotechnology as a dual-action approach against agricultural and clinical fungal pathogens.Archives of microbiology · 2026Review
- Article
- Dual-functional molecule 3c targeting CYP24A1-mediated 25-hydroxyvitamin D metabolism and microbial biofilms overcomes mixed vaginal infections.RSC advances · 2025Article
- Character Virulence Association Factors and Gene Mutation Mediating Multidrug Resistance Phenotypes in Candidozyma duobushaemulonii.Mycopathologia · 2025Article
- Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand.Mycoses · 2025Article
- In Silico and In Vitro Potential Antifungal Insights of Insect-Derived Peptides in the Management ofInternational journal of molecular sciences · 2025Article
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Understanding therapeutic tolerance through a mathematical model of drug-induced resistance.NPJ systems biology and applications · 2025Article
- Antifungal effect of soilIranian journal of microbiology · 2025Article
- Antifungal activity of polyphenolic compounds against fluconazole-susceptible and -resistantIranian journal of microbiology · 2025Article
- Antifungal Natural Products Originating from Endophytic and Rhizospheric Microbes Isolated from Coastal Vegetation.Journal of xenobiotics · 2025Review
- A Unique Case of Fungal Endometritis Caused byClinical case reports · 2025Article
- Activity of thonningianin A against Candida albicans in vitro and in vivo.Applied microbiology and biotechnology · 2024Article
- Review
- The Microevolution of Antifungal Drug Resistance in Pathogenic Fungi.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of serious fungal infections is increasing rapidly, and yet the rate of new drugs becoming available to treat them is slow. The limited therapeutic armamentarium is a challenge for clinicians, because the available drugs are often toxic, expensive, difficult to administer, ineffective or a combination of all four. Given this setting, the emergence of resistance is especially concerning, and a review of the topic is timely. Here we discuss antifungal drug resistance in Candida spp. and Aspergillus spp. with reference to the most commonly used first-line antifungal agents - azoles and echinocandins. We review the resistance mechanisms of the leading pathogens, how resistance can be identified in the diagnostic lab and the clinical implications of resistance once detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.